97 related articles for article (PubMed ID: 20560925)
1. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A; Niemi M
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):9-13. PubMed ID: 20560925
[TBL] [Abstract][Full Text] [Related]
2. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Smith NF; Marsh S; Scott-Horton TJ; Hamada A; Mielke S; Mross K; Figg WD; Verweij J; McLeod HL; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):76-82. PubMed ID: 17186002
[TBL] [Abstract][Full Text] [Related]
3. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
4. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
[TBL] [Abstract][Full Text] [Related]
5. SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.
Kim KA; Joo HJ; Lee HM; Park JY
Mol Biol Rep; 2013 Jul; 40(7):4211-7. PubMed ID: 23666051
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.
Justenhoven C; Schaeffeler E; Winter S; Baisch C; Hamann U; Harth V; Rabstein S; Spickenheuer A; Pesch B; Brüning T; Ko YD; Schwab M; Brauch H
Breast Cancer Res Treat; 2011 Jan; 125(2):563-9. PubMed ID: 20635135
[TBL] [Abstract][Full Text] [Related]
7. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
8. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
Sortica Vde A; Ojopi EB; Genro JP; Callegari-Jacques S; Ribeiro-Dos-Santos A; de Moraes MO; Romano-Silva MA; Pena SD; Suarez-Kurtz G; Hutz MH
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):460-8. PubMed ID: 22136368
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
Kim KA; Lee HM; Joo HJ; Park IB; Park JY
J Clin Pharmacol; 2013 Nov; 53(11):1186-93. PubMed ID: 23970434
[TBL] [Abstract][Full Text] [Related]
10. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
11. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
[TBL] [Abstract][Full Text] [Related]
12. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
13. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
14. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
[TBL] [Abstract][Full Text] [Related]
15. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
[TBL] [Abstract][Full Text] [Related]
16. Extreme differences in SLCO1B3 functional polymorphisms in Roma and Hungarian populations.
Nagy A; Szalai R; Magyari L; Bene J; Toth K; Melegh B
Environ Toxicol Pharmacol; 2015 May; 39(3):1246-51. PubMed ID: 26005078
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI; Meyer zu Schwabedissen HE; Tirona RG; Suzuki A; Leake BF; Mokrab Y; Mizuguchi K; Ho RH; Kim RB
Pharmacogenet Genomics; 2011 Mar; 21(3):103-14. PubMed ID: 21278621
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
Letschert K; Keppler D; König J
Pharmacogenetics; 2004 Jul; 14(7):441-52. PubMed ID: 15226676
[TBL] [Abstract][Full Text] [Related]
19. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S; Cheong HS; Kim JO; Kim LH; Na HS; Koh IS; Chung MW; Shin HD
Environ Toxicol Pharmacol; 2015 Nov; 40(3):692-7. PubMed ID: 26409184
[TBL] [Abstract][Full Text] [Related]
20. Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients.
Kunnari A; Ukkola O; Kesäniemi YA
Diabet Med; 2005 May; 22(5):583-9. PubMed ID: 15842513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
